Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Dr Sergey Suchkov, MD, PhD. Professor in Immunology & Medicine. Personal: Born 11 January 1957, Astrakhan, Russia. divorced; two sons. Education: MD, Astrakhan State Medical University, Russia, 1980; PhD, I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences, 1985; Doctor Degree, National Institute of Immunology, Russia, 2001. Positions held: Post Doc Research Associate, Institute of Medical Enzymology, 1985-87; Senior Research Associate, Koltzov Institute of Developmental Biology, USSR Academy of Sciences, 1987-89; Head of the Lab of Immunology and Immunobiotechnology, Helmholtz Eye Research Institute in Moscow, 1989-95; Trainee, Laboratory of Immunology, NEI, Bethesda, MD, USA, NIH and Laboratory of Immunology, Wills Eye Hospital, Philadelphia, USA, as well as at some of the British Universities on the invitation of the Royal Society for Immunology, 1989; Chairman, Department for Clinical Immunology, Moscow Clinical Research Institute and the Immunologist-in-Chief of the Moscow Regional Ministry of Health, 1995-2004; Executive Secretary-in-Chief of the Editorial Board, Biomedical Science International journal, 1993-1996; Professor in Medicine and Immunology, I.M. Sechenov First Moscow Medical University and Faculty Chairman & Director of the Department of Preventive, Personalized and Translational Medicine, A.I.Evdokimov Moscow State University of Medicine & Dentistry. Honours: Secretary General, United Cultural Convention, Cambridge, UK. Memberships: New York Academy of Sciences, USA; European Association for Predictive, Preventive and Personalized Medicine, Brussels; American Association for Research in Vision and Ophthalmology; International Society for Eye Research; EPMA Journal, Personalized Medicine Universe, Open J.Autoimmunity and American J.Cardiovascular Res. Editorial Boards; All-Union (from 1992 - Russian) Biochemical Society; All-Union (from 1992 - Russian) Immunological Society.
A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized and precision medicine (PPM) to stimulate the development in a variety of clinical disciplines including Personalized and Precision Oncology (PPO). To achieve the implementation of PPO concept into the daily practice, it is necessary to create a fundamentally new strategy based upon the subclinical recognition of cancer-associated bioindicators (biopredictors and biomarkers) of pre-cancer abnormalities long before the disease clinically manifests itself. Each decision-maker values the impact of their decision to use PPO on their own budget and well-being, which may not necessarily be optimal for society as a whole. It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and personalization of further treatment to thus provide more tailored measures for the cancer patients and persons-at-risk resulting in improved outcomes whilst securing the healthy state and wellness, reduced adverse events, and more cost effective use of health care resources. Rapidly improving understanding of PPO, emerging novel therapeutics, and increasingly available and affordable next-generation sequencing have created an opportunity for delivering genomically informed personalized cancer therapy. Alterations that are targetable either directly or indirectly with approved or investigational therapies are potentially "actionable." At this time, evidence linking predictive biomarkers to therapies is strong for only a few genomic markers in the context of specific cancer types. Deciding what therapy options to pursue can also be daunting, especially when tumors harbor more than one potentially actionable aberration. Further, different mutations/variants in a single gene may have different functional consequences, and response to targeted agents may be context dependent. However, early clinical trials with new molecular entities are increasingly conducted in a biomarker-selected fashion, and even when trials are not biomarker-selected, much effort is placed on enrolling patients onto clinical trials where they have the highest probability of response. Implementation of PPO requires a lot before the current model “oncologist-cancer patient” could be gradually displaced by a new model “medical advisor-healthy person-at-risk”. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPO to elicit the content of the new branch. Recognizing the need to define the policies required for sustained innovation in cancer research and care in an era of cost containment, the stakeholder community must engage in an ongoing dialogue and identify areas for collaboration.